ALK and neuroblastoma: Crizotinib and ceritinib are both under clinical evaluation for the treatment of ALK‐positive neuroblastomas with genetic ALK alterations, and our immunoassays allow for a direct pharmacodynamic preclinical comparison of the two compounds (Mosse et al., 2013).